Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients

Table 4

Subgroup analysis of comorbidities, treatment methodology including plasma exchange, or plasmapheresis between survivors and mortalities among 374 systemic lupus erythematosus patients.

	Survivors	Mortalities	value	Multivariate analysis	95% confidence interval
	352	22		value
Female	308	21	0.23
Comorbidities:
Rheumatoid arthritis	5	0	0.74
Systemic sclerosis	1	0	0.94
Sicca syndrome	7	0	0.65
Dermatomyositis	1	0	0.94
Polymyositis	1	0	0.94
Diabetes mellitus	5	2	0.06
Hepatitis, non-B, non-C	7	0	0.65
Gouty arthritis	1	0	0.94
Rheumatism	3	0	0.83
Hyperlipidemia	4	0	0.78
Hypertension	31	2	0.60
Bronchitis	1	0	0.94
Fibrositis	3	0	0.83
Cytomegalovirus infection	2	0	0.89
Chronic hepatitis B infection	1	0	0.94
Major depression	1	0	0.94
Chronic hepatitis C infection	1	0	0.94
Peripheral neuropathy	2	0	0.89
Therapy and examination:
Bone marrow biopsy	17	0	0.35
Kidney biopsy	21	0	0.27
Treatment methodology
Plasma exchange (PE)	309	15	0.02	0.02	0.12–0.81
Plasmapheresis (PP)	56	7	0.04	x	1
Death (PP versus PE)	15 vs. 7		0.04	0.02	3.21 (1.24–8.34)

indicates .